Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc.
February 26 2021 - 8:11AM
InvestorsHub NewsWire
Oncology Pharma Signs Worldwide
Licensing Agreement with Sybleu, Inc. for Commercialization of
Chemotherapeutic Agent in Combination with a Bioactive
Immunostimulatory Agent
San Francisco, CA -- February 26, 2021 -- InvestorsHub NewsWire
-- Oncology Pharma Inc. (OTC:
ONPH) is pleased to announce that it has executed a world-wide
Licensing Agreement with Sybleu Inc. for its Cancer therapy by
intratumoral injection of a chemotherapeutic agent in combination
with a bioactive immunostimulatory agent. The
chemotherapeutic agent of claim is AQ4 & AQ4N. The
bioactive agent is derived from the group of TNF-alpha, GM-CSF,
IL-4, IL-2, IL-12, IL-23, DNA, RNA, Nucleic Acids and CD-40
Ligand.
The concept of this invention is the simultaneous intratumoral
injection of a chemotherapeutic agents in combination with
immunomodulatory agents in sustained release formulations. The
chemotherapeutic agent is for the purpose of directly killing the
tumor cells for the release of antigens while the immunomodulatory
protein or factor is to stimulate the antigenic response of the
host to the antigens.
Oncology Pharma is excited about expanding its portfolio in
oncology and therapeutics. The Company sees a synergy within
the portfolio and is continuously building within its expertise
while utilizing its Board and Scientific Advisory Board to seek out
opportunities to enhance its position within the field of
oncology.
ABOUT ONCOLOGY PHARMA, INC
ONCOLOGY PHARMA, INC. (OTCPK:
ONPH) (the "Company") is currently engaging in research and
development of therapeutics for oncology and prides itself for
having a world-class Advisory Board that keeps the Company in the
forefront of developing technologies in cancer research,
biotechnology, and healthcare.
ABOUT SYBLEU INC.
SYBLEU INC. is a biotechnology company based in La Mesa,
California engaged in the development of regenerative medical
applications. Currently the Company is developing a patent
pending cancer therapy consisting of simultaneous intratumoral
injection of chemotherapeutic agents in combination with
immunomodulatory agents in sustained release formulations.
FORWARD LOOKING STATEMENTS
Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and
uncertainties in the Company's business that may cause actual
results to differ materially from those anticipated by the
statements made herein. Such risks and uncertainties include risks
related to licensing arrangements and joint ventures, including the
need to negotiate the definitive agreements for the relationships;
possible failure to realize anticipated benefits of business
relationships; and, costs of providing funding to these business
relationships. Other risks and uncertainties relating to the
Company include, among other things, current negative operating
cash flows and a need for additional funding to finance our
operating plan; the terms of any further financing, which may be
highly dilutive and may include onerous terms; unexpected costs and
operating deficits, and lower than expected sales and revenues;
uncertain willingness and ability of customers to adopt new
technologies and other factors that may affect further market
acceptance; adverse economic conditions; adverse results of any
legal proceedings; the volatility of our operating results and
financial condition; inability to attract or retain qualified
senior management personnel, including sales and marketing
personnel; our ability to establish and maintain the proprietary
nature of our technology through the patent process, as well as our
ability to possibly license from others patents and patent
applications necessary to develop products; the Company's ability
to implement its long range business plan for various applications
of its technology; the Company's ability to enter into agreements
with any necessary marketing and/or distribution partners and with
any strategic or joint venture partners; the impact of competition;
the obtaining and maintenance of any necessary regulatory
clearances applicable to applications of the Company's technology;
management of growth; and, other risks and uncertainties. This is
not a solicitation to buy or sell securities and does not purport
to be an analysis of the Company's financial position.
CONTACTS:
For additional Information, please contact the Oncology Pharma
at:
One Sansome Street, Suite 3500
San Francisco, CA 94104
Phone: 415-869-1038
Fax: 415-946-8801
Website: www.oncology-pharma.com
Email: info@oncology-pharma.com
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncology Pharma (CE) (USOTC:ONPH)
Historical Stock Chart
From Apr 2023 to Apr 2024